ArticleTranslational cancer research2025
Predictive value of random forest prediction model based on postoperative adjuvant transcatheter arterial chemoembolization therapy for survival of hepatocellular carcinoma patients with microvascular invasion: a retrospective cohort study.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Microvascular invasion (MVI), as an important stage of tumor cell invasion of blood vessels, is a key step for hepatocellular carcinoma (HCC) to metastasize into the liver and remote organs. Transcatheter arterial chemoembolization (TACE) is currently the most widely used adjuvant treatment after HCC surgery, which is used to treat tumor micrometastasis, and can inactivate residual tumor foci and reduce the recurrence rate. However, there is still controversy concerning its efficacy. The objective of our clinical study is to use propensity score matching and random forest models to determine whether HCC patients with MVI can benefit from postoperative adjuvant TACE therapy. Additionally, based on adjuvant TACE treatment, we aim to develop individualized random forest prediction models for the 5-year disease-free survival (DFS) rate and overall survival (OS) rate in HCC patients with MVI. Methods: Three hundred and twelve HCC patients with MVI and without MVI were divided into TACE and non-TACE (N-TACE) groups by propensity matching scoring method. Kaplan-Meier method was used to compare DFS and OS. Cox regression analysis evaluated the effect of adjuvant TACE on DFS and OS. The most influential characteristic variables of DFS and OS were used to construct the random forest prediction models. Results: After matching, the 1-, 3-, and 5-year DFS and OS of HCC patients with MVI in the TACE group were significantly higher than those in the N-TACE group (P<0.05). There was no significant difference in DFS and OS of HCC patients without MVI. Adjuvant TACE was an independent predictor of DFS and OS in HCC patients with MVI. Moreover, the random forest prediction models showed the key role of postoperative adjuvant TACE in DFS and OS of HCC patients with MVI. Conclusions: Postoperative adjuvant TACE improves the survival of HCC patients with MVI. The random forest prediction model has a good value for predicting the survival of HCC patients with MVI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.